Quantitative immunopet of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA a11 minibody

Journal of Nuclear Medicine

Volumn 55, Issue 3, 2014, Pages 452-459

  Knowles, Scott M ^a   Zettlitz, Kirstin A ^a   Tavaré, Richard ^a   Rochefort, Matthew M ^a   Salazar, Felix B ^a   Stout, David B ^a   Yazaki, Paul J ^b   Reiter, Robert E ^a   Wu, Anna M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

124I; 89Zr; Antibody fragments; Immuno PET; Minibody; Partial volume correction; Prostate cancer; Prostate stem cell antigen (PSCA)

Indexed keywords

DEFEROXAMINE; IODINE 124; PROSTATE STEM CELL ANTIGEN; PROSTATE STEM CELL ANTIGEN A11 MINIBODY; PROSTATE STEM CELL ANTIGEN A11 MINIBODY I 124; PROSTATE STEM CELL ANTIGEN A11 MINIBODY ZR 89; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ZIRCONIUM 89; DIAGNOSTIC AGENT; MINIBODY; RADIOACTIVE IODINE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; ZIRCONIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; DRUG UPTAKE; EX VIVO STUDY; IMAGE ANALYSIS; IMMUNOPET IMAGING; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; RADIATION DOSE DISTRIBUTION; 89ZR; ANIMAL; ANTIBODY FRAGMENTS; ARTIFACT; CELL TRANSFORMATION; IMMUNOLOGY; IMMUNOPET; MALE; METHODOLOGY; PARTIAL VOLUME CORRECTION; PROSTATE STEM CELL ANTIGEN (PSCA); PROSTATE TUMOR; SCINTISCANNING; TUMOR CELL LINE;

124I; 89ZR; ANTIBODY FRAGMENTS; IMMUNOPET; MINIBODY; PARTIAL VOLUME CORRECTION; PROSTATE CANCER; PROSTATE STEM CELL ANTIGEN (PSCA);

ANIMALS; ARTIFACTS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; IODINE RADIOISOTOPES; ISOTOPE LABELING; MALE; MICE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; SINGLE-CHAIN ANTIBODIES; ZIRCONIUM;

EID: 84899483754     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.120873     Document Type: Article

References (37)

1. Knowles SM, Wu AM. Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol. 2012;30:3884-3892.
2. Reiter RE, Gu Z,Watabe T, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA. 1998;95:1735-1740.
3. Han KR, Seligson DB, Liu X, et al. Prostate stem cell antigen expression is associated with Gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol. 2004;171:1117-1121.
4. Barbisan F, Mazzucchelli R, Santinelli A, et al. Expression of prostate stem cell antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer. Histopathology. 2010;57:572-579.
5. Gu Z, Thomas G, Yamashiro J, et al. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene. 2000;19:1288-1296.
6. Zhigang Z, Wenlv S. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer. Jpn J Clin Oncol. 2004;34:414-419.
7. Lam JS, Yamashiro J, Shintaku IP, et al. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res. 2005;11:2591-2596.
8. Amara N, Palapattu GS, Schrage M, et al. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res. 2001;61:4660-4665.
9. Wente MN, Jain A, Kono E, et al. Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas. 2005;31:119-125.
10. Ananias HJK, van den Heuvel MC, Helfrich W, de Jong IJ. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostatespecific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate. 2009;69:1101-1108.
11. Olafsen T, Gu Z, Sherman MA, et al. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother. 2007;30:396-405.
12. Leyton JV, Olafsen T, Lepin EJ, et al. Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clin Cancer Res. 2008;14:7488-7496.
13. Lepin EJ, Leyton JV, Zhou Y, et al. An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging. 2010;37:1529-1538.
14. Gagnon P, Cheung CW, Lepin EJ, et al. Minibodies and multimodal chromatography methods: a convergence of challenge and opportunity. Bioprocess Int. 2010;8:26-35.
15. Olafsen T, Sirk SJ, Olma S, Shen CKF, Wu AM. ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging. Tumour Biol. 2012;33:669-677.
16. Nayak TK, Brechbiel MW. Radioimmunoimaging with longer-lived positronemitting radionuclides: potentials and challenges. Bioconjug Chem. 2009;20:825- 841.
17. Herzog H, Tellman L, Qaim SM, Spellerberg S, Schmid A, Coenen HH. PET quantitation and imaging of the non-pure positron-emitting iodine isotope 124I. Appl Radiat Isot. 2002;56:673-679.
18. Lubberink M, Herzog H. Quantitative imaging of 124I and 86Y with PET. Eur J Nucl Med Mol Imaging. 2011;38(suppl 1):S10-S18.
19. Deri MA, Zeglis BM, Francesconi LC, Lewis JS. PET imaging with 89Zr: from radiochemistry to the clinic. Nucl Med Biol. 2013;40:3-14.
20. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48:932-945.
21. Jentzen W, Weise R, Kupferschläger J, et al. Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging. 2008;35:611-623.
22. Visser EP, Disselhorst JA, Brom M, et al. Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J Nucl Med. 2009;50:139-147.
23. Sanchez-Crespo A. Comparison of gallium-68 and fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot. 2013;76:55-62.
24. van Dongen GA, Visser GW, Lub-de Hooge MN, de Vries EG, Perk LR.Immuno- PET: a navigator in monoclonal antibody development and applications. Oncologist. 2007;12:1379-1389.
25. Tinianow JN, Gill HS, Ogasawara A, et al. Site-specifically 89Zr-labeled monoclonal antibodies for immunoPET. Nucl Med Biol. 2010;37:289-297.
26. Bao Q, Newport D, Chen M, Stout DB, Chatziioannou AF. Performance evaluation of the Inveon dedicated PET preclinical tomograph based on the NEMA NU-4 standards. J Nucl Med. 2009;50:401-408.
27. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:131-137.
28. Rousset GO, Zaidiy H. Correction for partial volume effects in emission tomography. In: Zaidi H, ed. Quantitative Analysis of Nuclear Medicine Images. New York, NY: Springer Science1Business Media; 2006:236-271.
29. Kessler RM, Ellis JR, Eden M. Analysis of emission tomographic scan data: limitations imposed by resolution and background. J Comput Assist Tomogr. 1984;8:514-522.
30. Ross S, Spencer SD, Holcomb I, et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res. 2002;62:2546-2553.
31. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23:1137-1146.
32. Schwartz J, Humm JL, Divgi CR, Larson SM, O'Donoghue JA. Bone marrow dosimetry using 124I-PET. J Nucl Med. 2012;53:615-621.
33. Börjesson PK, Jauw YW, Boellaard R, et al. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res. 2006;12:2133-2140.
34. Börjesson PKE, Jauw YWS, de Bree R, et al. Radiation dosimetry of 89Zrlabeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med. 2009;50:1828-1836.
35. Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr- DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010;51:1293-1300.
36. Jensen MM, Jørgensen JT, Binderup T, Kjaer A. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging. 2008;8:16.
37. Erlandsson K, Buvat I, Pretorius PH, Thomas BA, Hutton BF. A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology. Phys Med Biol. 2012;57:R119-R159.